{"entity":{"id":"plb-015","kind":"drug","name":"PLB-015","aka":[],"tldr":"PLB-015 is an experimental dual-payload antibody-drug conjugate from PrimeLink BioTherapeutics, in preclinical development for HER2-positive solid tumours.","summary":"PLB-015 is a dual-payload antibody-drug conjugate from PrimeLink BioTherapeutics. An anti-HER2 ADC carrying two payloads, a TOP1 inhibitor and an ATR inhibitor, designed to overcome resistance to TOP1 inhibitors. Its furthest stage is preclinical development, for HER2-positive solid tumours. No clinical trial naming it is registered on ClinicalTrials.gov. Preclinical poster at AACR 2026 (company release 2026-04-13). It has not been shown to work in people.","status":"preclinical","asOf":"2026-11-03","links":[{"label":"PrimeLink BioTherapeutics: en.primelinkbio.com","url":"http://en.primelinkbio.com/news_detail/16.html"}],"tags":["pipeline"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":["her2"],"drugs":[],"companies":["primelink-biotherapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"PLB-015","modality":"Dual-payload antibody-drug conjugate","mechanism":"An anti-HER2 ADC carrying two payloads, a TOP1 inhibitor and an ATR inhibitor, designed to overcome resistance to TOP1 inhibitors.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/plb-015/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"target":[{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/"}],"company":[{"id":"primelink-biotherapeutics","kind":"company","name":"PrimeLink BioTherapeutics","route":"/companies/primelink-biotherapeutics/"}]}}